We are live on ! Find out more
ADVM

Adverum Biotechnologies
ADVM

Delisted

ADVM was delisted on the 8th of December, 2025.

Back to rankings

100 hedge funds and large institutions have $192M invested in Adverum Biotechnologies in 2018 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 35 increasing their positions, 21 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,604% more call options, than puts

Call options by funds: $3.19M | Put options by funds: $187K

67% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 21

21% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 24

4% more funds holding

Funds holding: 96 → 100 (+4)

0.32% more ownership

Funds ownership: 5.57% → 5.89% (+0.32%)

4% less capital invested

Capital invested by funds: $201M → $192M (-$8.83M)

Holders
100
Holders Change
+4
Holders Change %
+4.17%
% of All Funds
2.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
35
Reduced
21
Closed
24
Calls
$3.19M
Puts
$187K
Net Calls
+$3M
Net Calls Change
-$225K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$15.7M
2
State Street
State Street
Massachusetts
+$4.97M
3
Citadel Advisors
Citadel Advisors
Florida
+$4.06M
4
JP Morgan Chase
JP Morgan Chase
New York
+$3.34M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.01M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$9.1M
2
Goldman Sachs
Goldman Sachs
New York
-$3.68M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$3.21M
4
NC
Nexthera Capital
New York
-$2.91M
5
HCM
Highbridge Capital Management
New York
-$2.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
26
Bridgeway Capital Management
Texas
$1M – – –
Bank of New York Mellon
27
Bank of New York Mellon
New York
$989K +$810K +13,471 +260%
RI
28
RTW Investments
New York
$935K +$6.98K +116 +0.7%
Axa
29
Axa
France
$871K +$749K +12,449 +313%
Connor, Clark & Lunn Investment Management (CC&L)
30
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$857K -$60.7K -1,010 -6%
Millennium Management
31
Millennium Management
New York
$823K -$9.1M -151,308 -91%
Victory Capital Management
32
Victory Capital Management
Texas
$820K -$53.2K -884 -5%
RPAM
33
Rhenman & Partners Asset Management
Sweden
$816K +$162K +2,696 +21%
VEA
34
Virtus ETF Advisers
New York
$763K +$866K +14,395 New
Morgan Stanley
35
Morgan Stanley
New York
$738K -$1.5M -24,891 -64%
TCIM
36
TIAA CREF Investment Management
New York
$641K +$727K +12,095 New
Charles Schwab
37
Charles Schwab
California
$603K +$684K +11,368 New
AAP
38
Ardsley Advisory Partners
Connecticut
$583K +$60.1K +1,000 +10%
TA
39
Teachers Advisors
New York
$554K +$628K +10,451 New
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
$463K +$329K +5,473 +167%
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$442K +$501K +8,332 New
Jacobs Levy Equity Management
42
Jacobs Levy Equity Management
New Jersey
$439K +$77.3K +1,286 +18%
AG
43
Algert Global
California
$436K +$56.1K +933 +13%
PA
44
Perceptive Advisors
New York
$428K – – –
CAM
45
ClariVest Asset Management
California
$311K +$3.01K +50 +0.9%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$292K +$331K +5,507 New
EAM
47
Exane Asset Management
France
$265K +$301K +5,000 New
MPAM
48
Monarch Partners Asset Management
Massachusetts
$243K +$54.1K +900 +24%
Manulife (Manufacturers Life Insurance)
49
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$232K +$255K +4,234 +3,415%
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$232K +$263K +4,380 New
1
2
3 4 5

ADVM Hedge Fund Activity: Q2 2018 in Review

100 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q2 2018, worth a combined $192M — down 4.4% from $201M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ADVM positions and 24 closed out — a net gain of 5 holders — while 35 added to existing stakes and 21 trimmed.

The largest buyer was BlackRock, adding an estimated $15.7M. The largest seller was Millennium Management, cutting an estimated $9.1M.

  • 100 institutional investors held Adverum Biotechnologies (ADVM) as of Q2 2018, up from 96 in Q1 2018.
  • Funds reported $192M of Adverum Biotechnologies stock for Q2 2018, down 4.4% quarter-over-quarter.
  • 29 funds opened new Adverum Biotechnologies positions in Q2 2018 and 24 closed out, a net change of +5 holders.
  • The largest Adverum Biotechnologies buyer in Q2 2018 was BlackRock, an estimated $15.7M added.
  • The largest Adverum Biotechnologies seller in Q2 2018 was Millennium Management, an estimated $9.1M sold.

Based on aggregated 13F filings for Q2 2018.